Energy rise without brown‑fat activation

A recent human trial shows a β2‑agonist (fenoterol) can raise measured energy expenditure without the expected activation of brown adipose tissue on PET/CT scans, implying other tissues or receptor pathways (or measurement limits) can drive thermogenesis. Negative results like this reveal mechanistic complexity and should reorient drug development away from single‑target hype toward multi‑pathway investigation and combined appetite/energy strategies. — This reframes a popular public narrative — that ‘turning on’ brown fat is a straightforward obesity cure — and has implications for how regulators, funders, clinicians, and the public judge weight‑loss claims and drug priorities.